Pat brings more than 20 years of leadership experience as a healthcare entrepreneur to his role as co-founder and CEO of Exai. He previously served as an Entrepreneur-in-Residence at the University of California, San Francisco Innovation Ventures. Prior to Exai and UCSF, Pat was co-founder and CEO for Bluestar Genomics, CEO for Critical Diagnostics, and a member of the founding management teams at Tethys Bioscience (acquired by HDL) and Intersect ENT (acquired by Medtronic). Pat began his career as a financial advisor and strategy consultant in the private equity industry, entering the diagnostic field as the turnaround CEO for First Medical (acquired by Sigma-Aldrich). He has a master’s degree in management from the Stanford Graduate School of Business and a bachelors degree in molecular biology from Princeton University.
Clinical Dx Showcase:
Exai Bio Inc
Exai Bio is a next-generation liquid biopsy company. Its mission is to enable a world where cancer can be detected early, diagnosed accurately, and treated in a personalized way. The company's propriety RNA and AI-based liquid biopsy platform delivers clinical insights into cancer biology.
Orphan Non-coding RNA (OncRNA): A Novel Liquid Biopsy Technology
Orphan non-coding RNAs (OncRNAs) are a novel technology platform, enabling a next-generation RNA-based liquid biopsy strategy.
The PMWC 2023 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.